NCT03485547 2026-02-02Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer InstitutePhase 1 Completed5 enrolled
NCT02730312 2022-03-08PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesXencor, Inc.Phase 1 Completed120 enrolled
NCT01231919 2014-04-29MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaNational Cancer Institute (NCI)Phase 1 Completed45 enrolled